- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04471337
Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function
March 25, 2024 updated by: Bayer
An Open-label Study to Evaluate the Pharmacokinetics and Safety of BAY 1817080 in Participants With Impaired Renal Function in Comparison to Matched Controls With Normal Renal Function
BAY1817080 is currently under clinical development to treat pain related to unexplained chronic cough or chronic cough not affected by a treatment (refractory and/or unexplained chronic cough, RUCC), or a condition where the bladder is unable to hold urine normally (overactive bladder, OAB) or a condition in which tissue similar to the tissue that normally lines the inside of the womb grows outside the womb (endometriosis).
Especially in elderly patients with OAB or RUCC, renal impairment is frequent.
Renal impairment which co-occurs in especially in elderly patients with OAB or RUCC is a common condition in which the kidneys are not filtering the blood as well as they should.
End stage renal disease (ESRD) requiring hemodialysis is a condition in which patients kidneys are no longer able to work as they should and require treatment to filter wastes from the blood.
The goal of the study is to learn more about the safety of BAY1817080, how it is tolerated and the way the body absorbs, distributes and excretes the study drug given in men and women with moderate renal impairment and with those who have end stage renal disease (ESRD) requiring dialysis compared with matched participants with normal kidney function.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33014
- Clinical Pharmacology of Miami, LLC
-
Orlando, Florida, United States, 32809
- Orlando Clinical Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 79 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Participant must be 18 to 79 years of age inclusive, at the time of signing the informed consent.
For renally impaired participants:
- Decreased renal function, as assessed based on serum creatinine collected 2 to 10 days prior to dosing and calculated according to the Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI) either: Moderately impaired renal function: eGFR: 30 to 59 mL/min/1.73 m^2; or ESRD on dialysis.
- Stable renal disease, i.e. a serum creatinine value determined 3 or more months before screening (e.g. during routine diagnostics) should not differ by more than 25% from the serum creatinine value determined at screening.
For participants with normal renal function:
-- Normal renal function, as assessed at screening and based on serum creatinine according to the CKD-EPI : eGFR ≥90 mL/min/1.73 m^2.
- Body mass index (BMI) within the range 18 to 38 kg/m^2 (both inclusive)
- Women of childbearing potential (WOCBP) must agree to use contraception for the duration of the study. This applies for the time period between signing of the Informed Consent Form until at least 30 days after the last dose of the study drug.
- Capable of giving signed informed consent as described in study protocol which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Exclusion Criteria:
- Any relevant disease (other than those related to renal impairment for the renal impaired participants) within 4 weeks prior to study drug administration including infections and acute gastro-intestinal diseases (vomiting, diarrhea, constipation) requiring medical treatment.
- Acute renal failure or acute nephritis within the past 2 years
- Use of strong CYP3A4 and P-glycoprotein inhibitors from 2 weeks before study treatment until last day of blood sampling for pharmacokinetics after study drug administration.
- Use of CYP3A4 and P-glycoprotein inducers from 2 weeks before study treatment until last day of blood sampling for pharmacokinetics after study drug administration.
- Use of drugs which may affect absorption (e.g. loperamide, metoclopramide), and systemic administration of any broad-spectrum antibiotic within 1 week before first study drug administration, unless the drug is part of the mandatory dosing regimen for treatment of renal impairment or related conditions.
- International Normalized Ratio (INR) > 2.3.
- Indication or evidence for long QT syndrome; Participants in control group only: QT interval corrected using Fridericia's method (QTcF) > 450 msec.
- Inability to provide informed consent: Participants with psychiatric disorders.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A: Moderately impaired renal function
Participants with moderately impaired renal function will receive multiple doses of BAY1817080.
|
BAY1817080 will be administered orally as tablet.
|
Experimental: Arm B: Normal renal function matched to Arm A
Participants with normal renal function matched to Arm A will receive multiple doses of BAY1817080.
|
BAY1817080 will be administered orally as tablet.
|
Experimental: Arm C: End stage renal disease on dialysis
Participants with ESRD requiring dialysis will receive single dose of BAY1817080.
|
BAY1817080 will be administered orally as tablet.
|
Experimental: Arm D: Normal renal function matched to Arm C
Participants with normal renal function matched to Arm C will receive single dose of BAY1817080.
|
BAY1817080 will be administered orally as tablet.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUCu after single dose of BAY1817080
Time Frame: On Day 1
|
AUCu: Area under the Curve unbound
|
On Day 1
|
Cmax,u after single dose of BAY1817080
Time Frame: On Day 1
|
Cmax,u: maximum observed drug concentration in measured matrix after single dose administration (unbound)
|
On Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects with treatment emergent adverse events (TEAEs)
Time Frame: From dosing up to 14 days after end of treatment with study medication
|
From dosing up to 14 days after end of treatment with study medication
|
|
AUC (0-12)md,u after multiple dose of BAY1817080
Time Frame: From Day 6 to Day 13
|
Area under the time curve from 0-12 hours at steady state for the multiple dose (unbound)
|
From Day 6 to Day 13
|
Cmax,md,u after multiple dose of BAY1817080
Time Frame: From Day 6 to Day 13
|
Cmax,md,u: Maximum observed drug concentration at steady state for multiple dose (unbound)
|
From Day 6 to Day 13
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 12, 2020
Primary Completion (Actual)
February 15, 2021
Study Completion (Actual)
May 6, 2021
Study Registration Dates
First Submitted
July 10, 2020
First Submitted That Met QC Criteria
July 10, 2020
First Posted (Actual)
July 15, 2020
Study Record Updates
Last Update Posted (Actual)
March 26, 2024
Last Update Submitted That Met QC Criteria
March 25, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Respiratory Tract Diseases
- Respiration Disorders
- Urologic Diseases
- Urinary Bladder Diseases
- Lower Urinary Tract Symptoms
- Urological Manifestations
- Pain
- Neurologic Manifestations
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Signs and Symptoms, Respiratory
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Cough
- Urinary Bladder, Overactive
- Neuralgia
- Endometriosis
- Chronic Cough
Other Study ID Numbers
- 20332 (UK NIHR CRN)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
There are no current plans to share data.
Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research.
Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overactive Bladder
-
Ankara Yildirim Beyazıt UniversityCompletedOveractive Bladder | Overactive Detrusor | Overactive Bladder SyndromeTurkey
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOveractive Bladder (OAB)United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
-
Medstar Health Research InstituteColumbia University; University of Michigan; University of New Mexico; Methodist...Terminated
-
Astellas Pharma Global Development, Inc.CompletedOveractive Bladder (OAB)United States, Canada
-
Merck Sharp & Dohme LLCTerminatedOveractive Bladder | Overactive Urinary Bladder
-
Loyola UniversityAstellas Pharma IncCompletedOveractive Bladder SyndromeUnited States
-
Beijing Pins Medical Co., LtdUnknown
-
Maastricht University Medical CenterUnknownLower Urinary Tract Symptoms | Overactive Bladder SyndromeNetherlands
-
Pamukkale UniversityCompletedElectrical Stimulation | Idiopathic Overactive Bladder | Bladder TrainingTurkey
Clinical Trials on BAY1817080
-
BayerCompletedRefractory and/or Unexplained Chronic CoughBelgium, Taiwan, Australia, Netherlands, Spain, Japan, United States, Germany, Turkey, United Kingdom, Argentina, Italy, Slovakia, Hungary, France, Canada, Czechia, Poland, Russian Federation
-
BayerCompletedOveractive Bladder | Diabetic Neuropathic Pain | Endometriosis Related Pain | Refractory or Unexplained Chronic CoughNetherlands
-
BayerTerminatedEndometriosisSpain, Belgium, United States, Germany, Austria, Japan, Canada, Hungary, Bulgaria, Italy, China, Czechia, Finland, Norway, Poland, Slovakia, Estonia, Greece, Latvia, Lithuania
-
BayerCompletedBiological AvailabilityNetherlands
-
BayerCompletedOveractive BladderAustria, Singapore, New Zealand, Australia, Portugal, Czechia, Poland, Germany, Sweden
-
BayerCompleted
-
BayerCompleted
-
BayerCompletedOveractive Bladder | Diabetic Neuropathic Pain | Endometriosis Related Pain | Refractory or Unexplained Chronic CoughJapan
-
BayerTerminatedNeuropathic Pain Associated With Diabetic Peripheral NeuropathyGermany, Denmark, France, Poland, Finland, Czechia, Hungary, Norway, Slovakia, Sweden
-
BayerCompletedOveractive Bladder | Cough | EndometriosisGermany